DLA Piper represents Parnell Pharmaceuticals in initial public offering

DLA Piper has advised Parnell Pharmaceuticals Holdings (PARN) in its initial public offering on NASDAQ.

PARN, an Australian-based veterinary pharmaceutical company with US operations located in Kansas City, Kansas, focuses on developing, manufacturing and commercialising innovative animal health solutions.

The company currently markets five products for companion animals and production animals in 14 countries and augments its pharmaceutical products with its proprietary software platforms.

The international DLA Piper team leading this cross-border offering included Andrew Gilbert, David Schwartz and Kirsten O’Donnell in New Jersey; Julia Kovacs and Linda Thomas in Baltimore; Michael Greenberg in New York; Rita Patel in Washington DC; David Morris, Simone Mitchell and Leah O’Brien in Sydney; and James Newnham in Melbourne.